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Abstract
Background: Following esophagectomy, esophageal cancer patients experience a clinically relevant deterioration
of health-related quality of life, both on the short- and long-term. With the currently growing number of
esophageal cancer survivors, the burden of disease- and treatment-related complaints and symptoms becomes
more relevant. This emphasizes the need for interventions aimed at improving quality of life. Beneficial effects of
post-operative physical exercise have been reported in several cancer types, but so far comparable evidence in
esophageal cancer patients is lacking. The aim of this study is to investigate effects of physical exercise on health-
related quality of life in esophageal cancer patients following surgery.
Methods: The Physical ExeRcise Following Esophageal Cancer Treatment (PERFECT) study is a multicenter randomized
controlled trial including 150 esophageal cancer patients after surgery with curative intent. Patients are randomly
allocated to an exercise group or usual care group. The exercise group participates in a 12-week combined aerobic and
resistance exercise program, supervised by a physiotherapist near the patient’s home-address. In addition, participants
in the exercise group are requested to be physically active for at least 30 min per day, every day of the week.
Participants allocated to the usual care group are asked to maintain their habitual physical activity pattern. The primary
outcome is health-related quality of life (EORTC-QLQ-C30). Secondary outcomes include esophageal cancer specific
quality of life, fatigue, anxiety and depression, sleep quality, work-related factors, cardiorespiratory fitness (VO2peak),
muscle strength, physical activity, malnutrition risk, anthropometry, blood markers, recurrence of disease and survival. All
questionnaire outcomes, diaries and accelerometers are assessed at baseline, post-intervention (12 weeks post-baseline)
and 24 weeks post-baseline. Physical fitness, anthropometry and blood markers are assessed at baseline and
post-intervention. In addition, adherence and safety are monitored throughout the exercise program.
Discussion: This randomized controlled trial investigates effects of physical exercise versus usual care in
esophageal cancer patients after surgery. As the design of the exercise program closely resembles daily practice,
this study can contribute both to evidence on effects of exercise in esophageal cancer patients, and to potential
implementation strategies.
Trial registration: Netherlands Trial Registry NTR5045
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Background
Age standardized (world population) incidence rates for
esophageal cancer have shown a rather steep upward
trend in the last decades in the Netherlands (from 3.73/
100,000 in 1990 to 6.89/100,000 in 2015) [1]. Further-
more, survival of esophageal cancer has slowly
improved over the past 25 years, as a result of improve-
ments in diagnosis and treatment of the disease [1, 2].
In the 30–40% of patients who are eligible for a poten-
tial curative treatment, the combination of surgery with
neoadjuvant chemoradiotherapy has provided a consid-
erable survival benefit compared to surgery alone
(Hazard Ratio: 0.78; 95% Confidence Interval (CI) 0.70
to 0.88) [3], leading to a 5-year survival of 47% in this
particular group of patients [4].
On the downside, a clinically relevant deterioration of
health-related quality of life (HRQoL) is observed both
during preoperative chemoradiotherapy and after esoph-
agectomy [5, 6]. After surgery, esophageal cancer
patients experience several disease- and treatment-
related problems, such as fatigue, eating difficulties, diar-
rhoea, nausea and vomiting, both on the short- and
long-term [7, 8]. In general, impaired HRQoL outcomes
last for 9–12 months, although some can even persist
beyond the first year after surgery [6, 9]. With a growing
number of esophageal cancer survivors, the burden of
disease- and treatment-related problems increases, and in-
terventions aimed at improving HRQoL are needed.
Several meta-analyses have shown beneficial effects of
physical exercise interventions after completion of treat-
ment on HRQoL [10–12]. Included randomized
controlled trials (RCTs) have been performed in various
cancer types, such as colorectal carcinoma, lymphoma
and, mostly, breast cancer. Since patient and treatment
characteristics of esophageal cancer patients are differ-
ent, results from these RCTs and meta-analyses may not
be directly generalizable to this patient population.
So far, no RCT has been performed to investigate
whether beneficial effects of physical exercise interventions
also apply for esophageal cancer patients. Therefore, the
Physical ExeRcise Following Esophageal Cancer Treatment
(PERFECT) study was initiated, to investigate the effects of
a 12-week combined aerobic and resistance exercise pro-
gram in esophageal cancer patients after surgery with
curative intent on health-related quality of life. In this
manuscript, we report the design of the PERFECT study.
Methods
Design
The primary aim of the PERFECT study is to investigate
effects of physical exercise on health-related quality of
life in esophageal cancer patients after surgery with
curative intent. In addition, we study the effects on
fatigue, physical fitness, physical activity, functional
wellbeing and symptoms, esophagus-specific QoL, anxiety
and depression, diet, sleep quality, anthropometry, work-
related factors and blood markers (secondary outcomes).
Furthermore, we will explore the effect of physical exer-
cise on disease recurrence and overall survival 5 years
after diagnosis. The PERFECT study is designed as a mul-
ticenter, randomized controlled trial with two study arms:
(1) a group offered a supervised exercise program in
addition to usual care and (2) a control group receiving
usual care without exercise intervention. We hypothesize
that physical exercise leads to higher levels of quality of
life, compared with usual care. The PERFECT study proto-
col has been approved by the Medical Ethics Committee
of the University Medical Center Utrecht in December
2014. The study is registered with the Netherlands Trial
Registry under NTR5045.
Participants
A total of 150 patients with esophageal cancer after sur-
gery with curative intent are planned to be included in
the PERFECT study. In order to be eligible for our study,
a participant must meet all of the following inclusion
criteria: surgery with curative intent for newly diagnosed,
histologically confirmed esophageal cancer; 4 weeks to
1 year after hospital discharge following surgery;
age ≥ 18 years; able to read and understand the Dutch
language; physically inactive (≤150 min per week of
moderate-vigorous exercise); Karnofsky Perfomance Sta-
tus ≥60; able to walk ≥60 m. Exclusion criteria are: pres-
ence of metastatic esophageal cancer; irradical resection;
contra-indications for physical activity (as assessed
through the Revised Physical Activity Readiness Ques-
tionnaire [13]). Patients who are already involved in a
supervised exercise program are also excluded. Written
informed consent is obtained from all participants prior
to participation in the study.
Depending on patient characteristics, surgical experi-
ence and preference, esophagectomy can be performed
through transthoracic or transhiatal approach. Both ap-
proaches, as well as the use of either open or minimally
invasive techniques for surgical resection, are allowed
for inclusion in the PERFECT study. Both patients with
and without neoadjuvant chemotherapy and/or radio-
therapy treatment are eligible for the study.
Recruitment and randomization
Participants are recruited from seven Dutch hospitals,
specialized in esophageal cancer treatment. Dependent
on recruitment rate, more hospitals might be invited to
collaborate. The recruitment and allocation procedure is
summarized in Fig. 1. Potentially eligible patients are in-
formed about the study by the oncology nurse or med-
ical specialist of each participating hospital. Interested
patients provide their contact information and receive a
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patient information letter explaining the study aims and
procedures. After 1 week, the investigator or research
nurse contacts the patients by telephone to provide fur-
ther information, answer remaining questions, and verify
inclusion and exclusion criteria. Eligible patients who are
willing to participate are invited to the study center to sign
written informed consent and for baseline measurements.
When participants have completed the baseline measure-
ments, they are randomly allocated (1:1) to either the
exercise intervention or usual care group, stratified by sex,
hospital and time since surgery. Randomization is per-
formed by central data management, using minimization.
Allocation to the exercise intervention or usual care group
is concealed. Due to the nature of the intervention, blind-
ing of the participants towards allocation is not possible.
After randomization, patients randomized to the inter-
vention group are informed on the supervised exercise
program and follow-up measurements. Those random-
ized to the control group are informed on the continu-
ation of usual care and the follow-up measurements.
The total study duration for every participant is about
24 weeks. Participants who choose not to participate in
the PERFECT study are asked to provide their reason for
non-participation.
Intervention
The standardized physical exercise program combines
aerobic and resistance training and takes place twice
weekly during 12 weeks. The individual components of
the exercise program are described below in the sections
‘Aerobic training’ and ‘Resistance training’. All exercise
sessions are supervised and guided by a physiotherapist,
preferably an oncology physiotherapist. Since esophageal
cancer care is centralized in the Netherlands, training at
the treating hospitals might not be feasible for some
patients due to relatively long travel distances. Before
start of the PERFECT study, we interviewed 4 esopha-
geal cancer patients, who all indicated a maximal travel
distance between 5 and 15 km as acceptable. Therefore,
the exercise program is offered close to home, either in
a general physiotherapist practice or in a hospital nearby
the patient’s home address. Each physiotherapist is
trained by the PERFECT study team to perform the
exercise sessions in a standardized way.
Although there is not yet enough evidence to draw
definite conclusions about the most effective design of
exercise programs [14], programs with moderate-to-
vigorous intensity have been shown to have significant
beneficial effects on HRQoL, whereas programs with
Fig. 1 Recruitment and allocation procedure
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mild-to-moderate intensity had not [11, 15]. With
regard to the mode of physical activity, the ACSM
guidelines on exercise for cancer survivors have
included both aerobic exercise and resistance exercise
[16, 17]. Therefore, we study the effectiveness of a
moderate-to-vigorous intensity program, combining
both aerobic and resistance exercise.
The exercise protocol has previously been shown to be
safe and feasible in healthy overweight, postmenopausal
women [18]. Exercise protocols with comparable content
and intensity have been shown to be safe and feasible in
patients with breast, colon, ovarian, cervix or testis can-
cer, or lymphomas [15, 19, 20]. The duration of every
exercise session is 1 hour and includes a warming up
(5 min), aerobic and resistance training (50 min) and a
cooling down (5 min). In case of physical limitations, an
adapted exercise program will be provided.
Aerobic training
The exercise protocol is individualized to the patient’s
fitness level using heart rate reserve (HRR) as deter-
mined at baseline with cardiopulmonary exercise testing
(CPET) for the aerobic training. The HRR represents the
change between heart rate in rest and peak heart rate.
Both parameters are tested at baseline with CPET, per-
formed at the sports medicine or lung function depart-
ment of the study center (see section ‘Study outcomes’).
The physiotherapist who supervises the exercise pro-
gram of the patient is informed about the HRR by the
PERFECT study team.
Levels of exercise intensity gradually increase during
the exercise program. During the first 3 weeks of the
training, the endurance training consists of 15–20 min
training on an exercise machine, e.g. a treadmill, exer-
cise bicycle or cross-trainer, at 40–60% of the HRR.
From the fourth until the eighth week of the training,
participants train 15–20 min at 60–70% of the HRR
and 5–10 min at 70–89% HRR. From the ninth week
onwards, participants train 10 min at 60–75% HRR,
and in addition they perform interval training: 10 × 30 s
vigorous to maximal exercise, alternated with a 1-min
active rest (Table 1). Participants wear heart rate
monitors to ensure exercise training at the prescribed
intensity.
Resistance training
For resistance training, the exercise protocol is also indi-
vidualized to the patient’s fitness level using 20-
repetition maximum (20-RM) muscle strength tests as
determined at the intake session by the physiotherapist.
Intensities increase from one set of 20–25 repetitions at
the 20-RM weight to a maximum of two sets of 15–20
repetitions at 15-RM weight (Table 1). To secure
sufficient training load throughout the training program,
the 20-RM muscle strength test will be repeated at week
4, and a 15-RM test will be determined at week 8, with
the resistance being adjusted accordingly. Resistance
training is performed for the major muscle groups and
consists of the following exercises: rowing, bench press,
squat, shoulder press, biceps curl, lunges, calf-raises,
triceps extension and abdominal crunch/hoover.
Home-based exercise
In addition to the supervised exercise program, partici-
pants are asked to be physically active for at least
30 min a day on all remaining days of the week, accord-
ing to the WCRF/AICR guidelines for cancer survivors
[21]. This should include an aerobic component of mod-
erate intensity in agreement with the participant’s fitness
and preferences. During an intake session, patients are
supported by their physiotherapist to set appropriate ex-
ercise goals. Participants document their activities daily
in an exercise log. Every 2 weeks, the exercise log is dis-
cussed with the physiotherapist, to evaluate progress of
physical activities and expand existing exercise goals
and/or set new exercise goals.
Usual care group
Participants in the usual care group receive usual care
and are requested to maintain their habitual physical
activity pattern.
Study outcomes
Table 2 summarizes the outcomes measured in the
PERFECT study. All questionnaire outcomes, diaries
and the accelerometers are assessed at baseline, post-
intervention (12 weeks post-baseline) and 24 weeks
post-baseline. At baseline and post-intervention these
outcomes are assessed during a study center visit. At
24-weeks participants receive the questionnaires by
mail. Physical fitness and blood markers are assessed at
baseline and post-intervention. Recurrence and survival
will be assessed 2- and 5-year post-diagnosis. Socio-
demographic data (age, sex, education, marital status)
Table 1 Exercise protocol
Week Aerobic training Resistance training
1–3 15–20 min 40–60% HRR One set of 20–25 repetitions
at 20-RM weight for each
exercisea4–8 15–20 min 60–70% HRR +
5–10 min 70–89% HRR
9–12 10 min 60–75% HRR + Interval
training: 10 × 30 s vigorous to
maximal exercise, alternated
with a 1-min active rest.
Two sets of 15–20 repetitions
at 15-RM weight for each
exerciseb
aRowing, bench press, squat, shoulder press, biceps curl, lunges,
calf-raises,
triceps extension, abdominal crunch
bRowing, bench press, squat, shoulder press, biceps curl,
triceps extension, abdominal crunch/hoover
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and smoking status are assessed at baseline with a self-
developed questionnaire. Medical data (diagnosis,
tumor type, disease stage, type of treatment, and
comorbidities) are retrieved from medical records.
Personal data are coded and all data are handled by the
researchers in compliance with the Dutch Personal
Data Protection Act. The PERFECT study is checked
on safety for participants and validity of data by an
independent monitor.
Quality of life
To measure HRQoL, the study’s primary outcome, the
global quality of life subscale of the validated, 30-item
European Organisation Research and Treatment of
Cancer-Quality of Life-C30 questionnaire (EORTC-
QLQ-C30; version 3) is used. For this study, the Dutch
translation of the EORTC-QLQ-C30 is used. In addition
to the quality of life subscale, the EORTC-QLQ-C30
incorporates five functional subscales (physical, role,
emotional, cognitive and social), three symptom scales
(fatigue, nausea & vomiting, and pain) and six single
items (dyspnea, insomnia, appetite loss, constipation,
diarrhea, and financial difficulties). All scale and item
scores range from 0 to 100. Higher scores on the global
quality of life subscale indicate a higher QoL. In the
functional subscales, a higher score is equivalent to
better levels of function, whereas in the symptom scales
and single items a higher score is indicative of more
symptoms [22].
Esophageal cancer specific problems are assessed
with the validated 25-item oesophagogastric module
(QLQ-OG25). This module consists of six symptom
scales: dysphagia, eating restrictions, reflux, odyno-
phagia, pain, and anxiety. Scores range from 0 to 100,
with higher scores representing more symptoms [23].
Fatigue
Fatigue is measured using the validated, Dutch version
of the Multidimensional Fatigue Inventory (MFI). The
MFI is a 20-item questionnaire, designed to measure the
following dimensions: general fatigue, physical fatigue,
mental fatigue, reduced activity and reduced motivation.
Scores range from 0 to 20, with higher scores indicating
more fatigue [24].
Anxiety and depression, sleep quality and work-related factors
Anxiety and depression are assessed using the Dutch
language version of the self-report Hospital Anxiety
and Depression Scale (HADS). The HADS consists of
two subscales, the depression subscale and anxiety sub-
scale. Both subscales have a score range from 0 to 21,
with higher scores indicating more depression or
anxiety [25, 26]. Sleep quality is assessed using the
Pittsburgh Sleep Quality Index (PSQI), which is a self-
administered questionnaire including four open-ended
questions and 14 questions based on a scale assessing
subjective sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbances, sleep-
promoting medication use, and daytime dysfunction
over the previous 1 month [27]. Work-related factors
Table 2 Study outcomes
Outcomes Instrument Baseline 12-week 24-week
Primary outcome
Quality of life EORTC-QLQ-C30 X X X
Secondary outcomes
Esophageal cancer
specific symptoms
EORTC-QLQ-OG25 X X X
Fatigue Multidimensional
Fatigue Inventory (MFI)
X X X
Anxiety and
depression
Hospital Anxiety
and Depression
Scale (HADS)
X X X
Sleep quality Pittsburgh Sleep
Quality Index (PSQI)
X X X
Work-related
factors
iMTA Productivity Cost
Questionnaire (iPCQ)
X X X
Cardiorespiratory
fitness
Cardiopulmonary
exercise testing (CPET)
X X
Muscle strength MicroFET handheld
dynamometer
X X
Physical activity Short questionnaire
to assess health
enhancing physical
activity (SQUASH)
X X X
ActiGraph
accelerometer
X X X
Exercise log X
Malnutrition risk Patient-Generated
Subjective Global
Assessment Short
Form (PG-SGA SF)
X X X
Dietary intake 3-Day food diary X X X
Anthropometry Body weight, height,
BMI, waist and hip
circumference
X X
Blood parameters Serum, plasma
and cell pellet
X X
Adherence
and compliance
Registration in case
report form, exercise
log
X X
Recurrence
and survival
Medical records and
Dutch Cancer Registry
Other
Sociodemographic
data
Self-developed
questionnaire
X
Medical data Medical records X
Adverse events Reports of patients,
physiotherapists,
oncology nurses,
physicians,
medical records
X X X
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are measured using the iMTA Productivity Cost
Questionnaire (iPCQ), which is developed as a self-
report instrument to measure and value productivity
losses, incorporating three modules: productivity losses
of paid work due to absenteeism, productivity losses of
paid work due to presenteeism, and productivity losses
related to unpaid work [28].
Physical fitness
Physical fitness is assessed as cardiorespiratory fitness
and muscle strength. Cardiorespiratory fitness is deter-
mined using symptom-limited CPET with continuous
breathing gas analysis on a bicycle ergometer, and is per-
formed under medical supervision. CPET is proven to
be safe for cancer patients prior to a physical exercise
program [29]. After a 1-min warm-up under no-load,
cycling workload is gradually increased with a predeter-
mined 10, 15 or 20 W per minute, depending on the pa-
tient’s condition. Patients are instructed to cycle with a
frequency of 70–80 rpm (revolutions per minute), until
exhaustion sets in. The test is terminated when cycling
frequency drops below 70 RPM or by decision of the
physician, and is followed by a 3-min cooling-down at
20 W. During the test, information is provided through
continuous 12-lead electrocardiography, blood pressure
monitoring and breath-by-breath analysis. Peak oxygen
uptake (VO2peak) is determined by taking the mean of
VO2 values of the last 30 s before exhaustion. In
addition, peak work load, peak heart rate and VO2 at
ventilatory threshold are assessed. In this study, per-
formance of CPET serves three goals: 1) measuring car-
diorespiratory fitness, 2) medical evaluation and exercise
clearance, and 3) determining the HRR at baseline to es-
timate individual training intensity for patients partici-
pating in the exercise program.
Muscle strength of quadriceps is measured with a
microFET2® hand held dynamometer, using the ‘break
technique’. Hereby, the patient is seated on an examin-
ation table with his/her knees in 900 flexion. The patient
is instructed to gradually increase knee extension force
to a maximum, and sustain for 3 s. The examiner then
overpowers this maximum, thereby providing a meas-
urement of eccentric force. The procedure is repeated
three times, for the left and right leg alternately, while
the patient is verbally encouraged. In case of a difference
of >10% between the two highest measurements, a
fourth measurement is taken.
Physical activity
Physical activity behavior is assessed using the short
questionnaire to assess health enhancing physical activity
(SQUASH), which includes items on commuting
activities, leisure time activities, household activities, and
activities at work and school [30].
To assess physical activities (duration/intensity) and
duration of sedentary behavior objectively, all partici-
pants wear an accelerometer (GT3X+ Tri-Axis Actigra-
phy Monitor, ActiGraph®) for seven consecutive days at
baseline and follow-up measurements. In addition,
participants in the intervention group are asked to keep
an exercise log during the exercise program. In this
exercise log, they document their daily activities.
Nutritional status and dietary intake
Malnutrition risk is detected at baseline and follow-up
using the Patient-Generated Subjective Global Assess-
ment Short Form (PG-SGA SF) [31, 32]. Furthermore,
dietary intake at baseline and follow-up measurements is
assessed using a 3-day food diary, which is filled out on
two non-consecutive week days and one weekend day.
Filled-in diaries are checked by a researcher or dietitian
and are, in case of incompleteness, complemented dur-
ing a telephone call with the participant. The food re-
cords will be coded and analyzed using the Dutch Food
Composition Database (Nevo 2013, National Institute
for Public Health and the Environment (RIVM), The
Netherlands).
Anthropometry
Before the CPET, body weight and height are measured
of participants wearing light clothes and no shoes. To
measure body weight, we use a calibrated analogue
balance and digital balance, depending on study center.
Analogue values are rounded to the nearest 0.5 kg.
Height is measured using a wall mounted tape measure,
with values rounded to the nearest 0.5 cm. The same
balance and tape measure are always used for all mea-
surements of an individual participant. Body Mass Index
(BMI) is calculated as weight in kilograms divided by
height in meters squared (kg∙m−2). Waist and hip
circumference (to the nearest 0.5 cm) are measured
standing at the midway between lower ribs and iliac
crest, and as the largest circumference between waist
and thigh, respectively. Measurements are taken in
duplicate and averaged.
Blood collection
Serum, plasma and cell pellet are derived from whole
blood samples, processed within 4 hours and stored at
-80 °C in the biobank of the University Medical Center
Utrecht to be used for future analyses of biomarkers.
Adherence
Adherence incorporates both attendance at the super-
vised exercise sessions and compliance (i.e., performing
the exercises according to exercise protocol). To moni-
tor attendance, the physiotherapist documents presence
of each participant at each session in a case report form.
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Furthermore, to monitor compliance, achieved heart
rates and duration for the aerobic exercise components
are documented, and weight and number of repetitions
performed for the resistance components. In case of
missed exercise sessions or non-compliance to the
protocol, reasons are documented. At least every 4
weeks, this documentation is sent to the researchers for
monitoring. Moreover, each physiotherapist is visited at
least once by a member of the PERFECT study team, to
ensure proper performance of the exercise protocol.
Recurrence and survival
Information on cancer recurrence, new primary tumors
and (all-cause) death is retrieved from medical records
and the Dutch Cancer Registry.
Safety
CPET with electrocardiography is performed for exercise
clearance before start of the exercise training. Adverse
events reported by the patient or observed by physio-
therapists, oncology nurses or physicians are recorded
and serious adverse events are reported to the medical
ethical committee. Malnutrition, dysphagia and weight
loss are common problems in esophageal cancer patients
[7], hence weight loss is not a goal of the exercise pro-
gram. Body weight is therefore closely monitored by
weekly supervised weighing by the physiotherapist. All
physiotherapists are instructed to contact the researchers
if weight loss exceeds 5% in 1 month, or 10% in total,
upon which the study team will consult a dietitian or
medical specialist.
Sample size
The sample size is based on the primary outcome; im-
provement in HRQoL from baseline to post-
intervention, assessed by the EORTC-QLQ-30. In our
previous trial [33, 34], investigating the effects of a 12-
week exercise training in cancer survivors, HRQoL in
the intervention group improved by 15.1 (SD 17.7)
points and the control group by 6.1 (SD 17.1) points;
this difference was significant and clinically relevant
[35]. We performed a power analysis with PASS, using
these results and assuming a power of 80% (alpha = 0.05),
which showed that 60 patients are needed in each group
to detect an intervention effect. To take into account the
correlation between baseline and follow-up in the sam-
ple size calculation, Borm et al. developed a method to
calculate the sample size, in which the previously calcu-
lated number of subjects, should be multiplied by (1-ρ2),
plus one extra subject per group [36]. ρ represents the
correlation between baseline and follow-up outcomes. In
our previous trials we found a correlation of 0.4 between
baseline and follow-up HRQoL. By applying the method
of Borm et al., we have calculated a sample size of 51
patients per group. We intend to include 75 patients per
group taking a drop-out rate of approximately 30% into
account (primarily due to early death). This sample size
also enables us to detect intervention effects on the sec-
ondary outcomes (e.g. physical functioning, VO2peak and
fatigue). If drop-out appears to be lower, less patients
per group can be included (e.g. in case of a drop-out rate
of 10%, 57 patients per group can be included).
Statistical analysis
Descriptive statistics will be used to describe the study
population and study parameters at baseline. Question-
naire scores (e.g. HRQoL and fatigue) will be calculated
according to published scoring algorithms. Analyses will
be performed according to the intention-to-treat
principle. For the primary analysis mixed linear regres-
sion models will be used to model the HRQoL outcome
measures at 12 and 24 weeks. The models will be ad-
justed for baseline HRQoL as well as for stratification
factors. In these longitudinal analyses, the program ac-
counts for missing data based on the observed data [37].
The same analyses will be performed for the secondary
outcome measures. Secondary outcomes, which will only
be assessed at baseline and 12 weeks (e.g. VO2peak), will
be analyzed as between-group differences in outcomes
using ANCOVA, adjusted for baseline and stratification
factors. Cancer recurrence and survival will be analyzed
using a Cox proportional hazards regression model. As
an explorative analysis, attendance and compliance, sex,
subtype of carcinoma, type of surgery and time since
surgery will be examined as potential modifiers of the
intervention effects. Furthermore, to adjust for treatment
contamination, an instrumental variable analysis will be
performed with treatment assignment as instrument and
adjustment of the results for adherence [38].
Discussion
The aim of the PERFECT study is to investigate effects
of exercise on HRQoL in esophageal cancer patients
after surgery. Results of exercise on HRQoL in other
types of cancer are promising, however effects in
esophageal cancer patients have not been assessed
before.
A special feature of the current study is the supervi-
sion of the exercise program by physiotherapists near
the home-address of the participants who are random-
ized to the intervention group. As this approach dimin-
ishes travel burden considerably, we expect it to improve
adherence of the participants. It might be challenging
though, as for each individual participant an appropriate
physiotherapist needs to be identified and trained, dir-
ectly after randomization into the intervention group.
However, as the Dutch (oncology) physiotherapy com-
munity is an expanding and highly motivated group of
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health care professionals, we expect this procedure to
be feasible. Moreover, since this approach strongly
resembles the real world situation, results of the study
will be well generalizable and, as a consequence of
developing a network of trained physiotherapists across
the country during the study, an ideal situation is cre-
ated for future implementation of the exercise program,
if proven effective.
Within the field of exercise-oncology, results can be
affected by two features. First, effects of the exercise pro-
gram in the intervention group might be influenced by
adherence. Both non-attendance and non-compliance
decrease (exercise) treatment dose, thereby resulting in
smaller effect sizes. In order to increase attendance and
compliance, we implemented several strategies in our
study design. In addition to the short distance to the
training facilities, these consist of individual guidance by
a trained and experienced physiotherapist, an individual-
ized exercise protocol and regular phone calls with the
research team. Though attendance and compliance are
important, in studies they are rarely reported [39]. In the
present study, attendance and compliance to the super-
vised exercise program will be strictly registered by the
physiotherapist and regularly checked by the researchers,
while the documented activities in the exercise log of the
participants enable us to calculate compliance with the
exercise advice.
Second, effects of the exercise program might be influ-
enced by so-called contamination (non-compliance) of
the usual care group. This phenomenon is reported to
occur in 37% of exercise-oncology trials and is caused by
the fact that patients who participate in these type of tri-
als are often highly motivated to exercise, which subse-
quently leads to an increase of physical activity levels,
not only in patients randomized to the intervention
group, but also in those randomized to the usual care
group [40]. To prevent contamination, we include phys-
ically inactive patients (i.e., they might have less natural
preference to adapt high physical activity levels when
randomized to usual care), elaborate on the randomized
design during the informed consent procedure in order
to avoid disappointment when being randomized to the
usual care group, and repeatedly stress the importance
of the usual care group during the inclusion period.
After completion of the trial, patients who were random-
ized to the usual care group can ask the study team for
an exercise advice.
In conclusion, the PERFECT study is the first study
to investigate effects of an exercise program in esopha-
geal cancer patients after surgery. As the design closely
resembles daily practice, results of this study can con-
tribute both to evidence on effects of exercise in
esophageal cancer patients, and potential implementa-
tion strategies.
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